WASHINGTON — The Trump administration is pushing pharmaceutical firms to start negotiations to deliver their drug costs in step with what different international locations pay — normally far lower than People.
“Below President Trump’s path, HHS is demanding that pharmaceutical firms finish their obstruction and are available to the desk—simply as they already do with practically each different economically comparable nation—to barter honest, clear pricing for People,” an company spokesperson mentioned in a press release to STAT, including that the businesses had been “forestall[ing] progress of reducing costs for the American folks.”
The spokesperson didn’t instantly make clear how firms had been stopping that progress. The administration’s assertion comes after pharmaceutical executives mentioned they had been anticipating extra particulars in regards to the sorts of medicine that may be up for negotiations and the worth targets for them.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day intelligence on Capitol Hill and the life sciences trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
